Xefo (lornoxicam) / Old API Wind-down, Takeda - LARVOL DELTA

Efficacy of Chemically Distinct Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and Pain Phenotypes in Adhesive Capsulitis (clinicaltrials.gov) - P=N/A | N=120 | Recruiting | Sponsor: Konya Beyhekim Training and Research Hospital

New trial • Musculoskeletal Pain • Neuralgia • Pain

Development and Evaluation of Multiple-Unit Tablets for the Controlled Release of Lornoxicam. (PubMed, Drugs R D) - "The developed biphasic-release MUTs provide rapid onset, sustained LOX delivery, and reliable dose flexibility, representing a promising oral formulation for LOX therapy."

Journal • Pain

Drug-induced upper gastrointestinal bleeding: A real-world pharmacovigilance study. (PubMed, PLoS One) - "This study conducted a pharmacovigilance analysis of drug-related UGIB by integrating and analyzing multiple adverse drug reaction databases. In both the FAERS and JADER databases, we not only identified some common risk-signaling drugs but also discovered database-specific risk-associated medications. In particular, this study performed a systematic quantitative risk assessment of the selected high-reporting-frequency drugs. This analysis not only deepened our understanding of drug risk profiles but also provided important reference evidence for clinical medication safety decision-making."

Adverse events • Journal • Real-world evidence • Gastroenterology

Transdermal Delivery of Lornoxicam via Transethosomal Gel as a Novel Strategy for Management of Rheumatoid Arthritis. (PubMed, Drug Dev Ind Pharm) - "The developed LOR-TES gel enhanced transdermal drug delivery, offering sustained release and improved permeation. It presents a promising strategy for effective management of rheumatoid arthritis through the transdermal route."

Journal • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

The effect of methylene blue infiltrating injection on anal pain after Milligan-Morgan surgery: A randomized controlled clinical study. (PubMed, Medicine (Baltimore)) - "MBI provides effective and safe analgesia after Milligan-Morgan surgery, significantly reducing pain, analgesic consumption, hospital stay, and cost."

Clinical • Journal • Cardiovascular • Dermatology • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Pain • Thrombosis

Intelligent feature extraction for anaerobic/anoxic/aerobic process in municipal wastewater treatment plant. (PubMed, J Environ Sci (China)) - "Finally, the effectiveness of SAFEM is illustrated with experimental studies from a real MWWTP in China. The abnormal condition diagnosis performance of SAFEM shows that SAFEM can extract MWWTPs features accurately."

Journal

Development of machine learning predictive models for estimating pharmaceutical solubility in supercritical CO2: case study on lornoxicam solubility. (PubMed, Front Chem) - "This comparative framework illustrates the bias-variance tradeoff and offers pragmatic guidance for choosing suitable models according to dataset attributes. The methodology presents a time-efficient and cost-effective alternative to conventional thermodynamic modelling for supercritical pharmaceutical processing."

Journal

Lipid-chitosan hybrid nanoparticles for transdermal co-delivery of lornoxicam and curcumin in arthritis management. (PubMed, Int J Biol Macromol) - "These findings suggest that the developed LPHNPs are promising vehicles for the transdermal co-delivery of lornoxicam and curcumin for inflammation treatment and management. However, further investigations into the toxicity profile and subacute pharmacological effects are recommended."

Journal • Immunology • Inflammation • Rheumatology

Early application of modified A-OK protocol for amniotic fluid embolism: Case series report. (PubMed, Medicine (Baltimore)) - "These cases suggest that early A-OK-based therapy (or its modified A-GL regimen) may improve outcomes in AFE. Further research is warranted to validate this approach and refine treatment protocols."

Journal • Cardiovascular • Hematological Disorders • Obstetrics

Impact of Different Drying Processes on the Physico-Chemical Properties of Liquitablet Formulations Containing Lornoxicam. (PubMed, Pharmaceutics) - "A similarity was observed between our freeze-dried product and the marketed fast-release tablets. This research demonstrates that preparation of liquitablet in combination with freeze-drying has a significantly positive effect in improving the in vitro dissolution rate of lornoxicam."

Journal

Lipid Raft Membrane Interactivity Correlating with Cyclooxygenase-2 Selectivity of Non-Steroidal Anti-Inflammatory Drugs. (PubMed, Membranes (Basel)) - "Conventional NSAIDs (diclofenac, ibuprofen, indomethacin, aspirin, and flurbiprofen) and Coxibs (lumiracoxib, etoricoxib, celecoxib, valdecoxib, and rofecoxib) decreased membrane fluidity, whereas Oxicams (meloxicam, piroxicam, tenoxicam, and lornoxicam) increased. Under inflammatory acidic conditions, the lipid raft membrane interactivity of NSAIDs was more likely to correlate with cyclooxygenase-2 selectivity than the reference membrane interactivity. It is hypothesized that NSAIDs may interact with lipid raft membranes to induce membrane fluidity changes with the potency corresponding to cyclooxygenase-2 inhibition, disrupting the structural and functional integrity of lipid rafts to affect the activity of cyclooxygenase-2 localized in lipid rafts, resulting in cyclooxygenase-2 selective inhibition."

Journal

RETRACTION: Safety and Efficacy of Pre-Incisional Peritonsillar Lornoxicam in Paediatric Post-Tonsillectomy Pain: A Prospective Double-Blind, Placebo-Controlled, Split-Body Clinical Study. (PubMed, Clin Otolaryngol) - "Therefore, the parties agree that the article must be retracted. The authors disagree with the retraction."

Journal • Otorhinolaryngology • Pain • Pediatrics

Antithrombotic potential of lornoxicam and possible mechanistic pathways. (PubMed, J Pharmacol Exp Ther) - "SIGNIFICANCE STATEMENT: The in silico, in vitro, and in vivo experiments in this study revealed the excellent antithrombotic potential and protective effect of lornoxicam on myocardial infarction and pulmonary embolism, even at lower doses. This study proposes that lornoxicam treatment, just like aspirin, at lower doses could be an appropriate prophylactic option in patients who are more prone to myocardial infarction and pulmonary embolism."

Journal • Cardiovascular • Hematological Disorders • Myocardial Infarction • Oncology • Pain • Pulmonary Embolism • Respiratory Diseases • TNFA

An injectable ropivacaine and lornoxicam sustained-release gel regulated by low molecular weight poly(ortho esters). (PubMed, Pharm Dev Technol) - "Compared to commercial products, RL-SRG prolonged the time of peak concentration (Tmax), mean residence time (MRT), and elimination half-life (t1/2), as well as possessed similar the area under the plasma concentration-time curve (AUC0-t). Therefore, RL-SRG has been validated as a novel sustained release system to the application for the long-term treatment of postoperative pain."

Journal • Anesthesia • Pain

Application of particle swarm optimization to non-orthogonal error correction in SAFEM total magnetic intensity measurements. (PubMed, Rev Sci Instrum) - "Experiments with a physical measurement system further validated the method's efficacy: after calibration, the maximum absolute error and the RMSE of the TMI were significantly reduced by 82.84% and 87.64%, respectively. This study provides a critical technical solution for the complex, multi-parameter error calibration of alternating current vector magnetometers, ensuring the acquisition of high-precision TMI data for SAFEM systems."

Journal

Comprehensive Analysis of Gastrointestinal Injury Induced by Nonsteroidal Anti-Inflammatory Drugs Using Data from FDA Adverse Event Reporting System Database. (PubMed, Pharmaceuticals (Basel)) - "Cyclooxygenase-2 (COX-2) selective NSAIDs (e.g., celecoxib, rofecoxib) were associated with a lower incidence but greater severity, primarily in the upper GI tract. Conversely, nonselective NSAIDs (e.g., acetylsalicylic acid, lornoxicam) showed higher incidence rates, though the events were generally milder. In our dataset, acetylsalicylic acid had the highest incidence, whereas meloxicam showed the highest severity... NSAIDs differ significantly in their gastrointestinal adverse event profiles, attributable to COX selectivity. When selecting an NSAID, both the likelihood and the nature of potential GI harm should be considered."

Adverse events • Journal • Gastroenterology • Gastrointestinal Disorder

Postoperative analgesic efficacy of preemptive and postoperative lornoxicam in femoropopliteal bypass surgery. (PubMed, Agri) - "Regardless of the time it is applied, lornoxicam reduces postoperative pain and consumption of opioids within the initial 3 hours."

Journal • Pain

Influence of Orange Oil on Skin Permeability, Dermatokinetics, and In Vivo Anti-inflammatory Properties of Lornoxicam-loaded Niosomal Gel. (PubMed, Curr Drug Metab) - "The study concluded that orange oil enhanced skin permeability and influenced the derma-tokinetics of the LOR-OR-NIO gel, leading to an improvement in in vivo anti-inflammatory properties."

Journal • Preclinical

Comparative study of the efficacy and safety of combined therapy with lornoxicam (Xefokam Rapid) and a nucleotide complex Xefomielyn in patients with exacerbation of chronic nonspecific low back pain (PubMed, Zh Nevrol Psikhiatr Im S S Korsakova) - "The data obtained indicate high clinical efficacy and a favorable safety profile of combination therapy with Xefocam Rapid and Xefomyelin in patients with CLBP."

Clinical • Journal • Back Pain • Lumbar Back Pain • Musculoskeletal Pain • Pain

Regenerated cellulose fibers for preparation of alginate and lornoxicam-loaded medical knitted textiles: A response surface optimization study. (PubMed, Int J Biol Macromol) - "The studied formulations followed different LRX release models suggesting erosion, Fickian, non-Fickian diffusion, and super case II mechanisms. A multiple-response optimization was employed, and the proposed design of experiments enabled the prediction of the optimal factors' levels required for the target responses."

Journal

Multimodal evaluation of lipoxygenase-targeting NSAIDs using integrated in vitro, SAR, in silico, cytotoxicity towards MCF-7 cell line, DNA docking and MD simulation approaches. (PubMed, Int J Biol Macromol) - "We reported earlier that several NSAIDs, including naproxen, aspirin and acetaminophen, inhibited lipoxygenase (LOX) enzyme at sub-micromolar concentrations...Aceclofenac (IC50 0.85 ± 0.06 μM) was the most active drug, followed by indomethacin (IC50 1.13 ± 0.07 μM), meloxicam (IC50 1.94 ± 0.07 μM) and ketorolac (IC50 9.26 ± 0.82 μM). Celecoxib (IC50 15.81 ± 0.71 μM), lornoxicam (IC50 16.54 ± 0.28 μM) and nimesulide (IC50 19.87 ± 0.85 μM) showed excellent inhibitory profiles. Flurbiprofen (IC50 21.73 ± 0.93 μM) and etoricoxib (IC50 24.93 ± 0.64 μM) moderately inhibited the target enzyme...Density functional theory (DFT) and ESP studies, MD simulations and MMPBSA free energy calculations further reiterated the stability of ligand-receptor complexes. Overall, these findings highlight the potential of targeted NSAIDs as dual COX/LOX inhibitors with broader therapeutic relevance in inflammatory disorders."

Journal • Preclinical • Breast Cancer • Oncology • Solid Tumor

In vitro-in vivo scaling of cytochrome P450-mediated metabolic clearance using a relative activity factor approach. (PubMed, Drug Metab Dispos) - "We selected multiple probe substrates for CYP1A2 (caffeine, tizanidine, phenacetin), CYP2C9 ((S)-acenocoumarol, glimepiride, lornoxicam, tolbutamide, (S)-warfarin), CYP2C19 ((S)-lansoprazole, omeprazole, pantoprazole), CYP2D6 (desipramine, metoprolol, nebivolol, tolterodine), and CYP3A4 (alprazolam, felodipine, midazolam, nisoldipine, sildenafil, triazolam) to calculate the representative RAF value for each P450 isoform based on the in vivo-to-in vitro clearance ratio of the multiple probe substrates...The fm values of the responsible P450 isoform(s) could be well predicted for mexiletine, tamsulosin, risperidone, celecoxib, and glibenclamide...By applying relative activity factor values obtained from multiple probe substrates, this study was able to quantitatively predict the in vivo clearances mediated by CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. This simple, practical method will help optimize metabolic clearances via the major cytochrome P450..."

Journal • Preclinical • CYP1A2 • CYP2C19 • CYP2C9 • CYP3A4

Nonsteroidal anti-inflammatory drugs (NSAIDs) for acute renal colic. (PubMed, Cochrane Database Syst Rev) - "NSAIDs may reduce pain in adult patients with renal colic compared to placebo. Comparing one NSAID against another, IV ketorolac may be less effective than IV ibuprofen, and pirprofen may result in less need for rescue medication than indomethacin. The intravenous route of administration is probably similar to the intramuscular route but may be better than the rectal route. The evidence is uncertain regarding the potential harms of NSAIDs. We were not able to perform subgroup analysis based on our predefined criteria because there were no eligible studies."

Clinical • Journal • Review • Inflammation • Pain • Renal Calculi • Urolithiasis

Revolutionizing Drug Delivery: A Design Professional's Approach to Drug-loaded Transferosomal Vesicles for Transdermal Use. (PubMed, Pharm Nanotechnol) - "The study concludes that formulation TDP-8, which incorporates 3g of Aloe vera leaf mucilage (AVLM) and lime oil (LO) as permeability enhancers, demonstrated favorable discharge characteristics. This indicates its potential as an effective transdermal delivery system for LXM and TCS, offering a promising substitute for pain and inflammation relief while minimizing gastric irritation. The study succeeded in developing and evaluating transferosomal transdermal patches for LXM and TCS, providing an alternative delivery method that minimizes gastric irritation."

Journal • Inflammation • Pain

Formulation, Optimization, and Evaluation of Lornoxicam-Loaded Novasomes for Targeted Ulcerative Colitis Therapy: In Vitro and In Vivo Investigations. (PubMed, J Drug Target) - "At the same time, it elevated Silent information regulator-1(SIRT-1) and reduced glutathione (GSH) colon contents. Thus, the current study suggested that the formulation of LOR- Novas may be a viable treatment for ulcerative colitis."

Journal • Preclinical • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis • TLR4